Recently, Hengrui Medicine's application for the 4 generic drug "Sugeng Sodium Gluconate Injection" (CYHS1900711/712 after the relevant acceptance) has entered the administrative examination and approval stage, and it is expected to be formally approved soon, becoming the first domestically approved product Shu more sodium gluconate injection.

Sugan Gluconate is the world's first selective muscle relaxation antagonist for reversing neuromuscular blockers. Residual neuromuscular blockade refers to the use of muscle relaxants in patients during surgery. After the operation, the neuromuscular function has not returned to normal levels and the breathing, vision, swallowing and other functions are restricted, which can cause severe postoperative breathing. Dysfunction directly threatens the lives of patients. This product can help patients under general anesthesia accurately and quickly reverse the deep and moderate muscle relaxation in clinical surgical anesthesia, promote patients to recover spontaneous breathing and limb mobility, and help improve the patient's postoperative outcome. It has been in the field of anesthetics for 20 years The first major drug development.

Sugan Gluconate was developed by Merck and was listed in the European Union in September 2008, in the United States in December 2015, and in China in April 2017. Currently, Bridion has been approved for listing in more than 70 countries around the world. According to reports, global sales in 2018 were 917 million U.S. dollars, and sales continued to grow, reaching 1.198 billion U.S. dollars in 2020. It is a quasi-blockbuster drug. The market is still on the rise and the market is performing well.

According to public information, the domestic compound patent of sugammadex in China has expired on November 23, 2020. However, because sugammadex sodium is a polysaccharide compound, there are many reaction sites and the reaction process is complicated, so strict control is required. The reaction conditions and post-processing conditions are required to obtain qualified intermediates, and then obtain qualified APIs.

At present, in China, only the original research Sodium Gluconate has been approved for listing, and there is no domestic market, and there is no approval for domestic and imported Sodium Gluconate. The competition is relatively good. Our company can supply imported Sodium Gluconate raw materials with competitive prices. Welcome new and old customers to consult.